In patients with type 2 diabetes (T2D) and metabolic dysfunction–associated steatotic liver disease (MASLD), the risk for major liver outcomes appears similar with dipeptidyl peptidase 4 (DPP-4) and ...
Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback